XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 40% planned / 60% discretionary
Largest single sale: $640.6K.
Where they traded
Last open-market purchase: September 30, 2026 , by Kelly Thomas Patrick .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO | Buy | 30,000 | $37.38 | $1.1M | 49,923 | |
| Kelly Thomas Patrick | Chief Financial Officer | Buy | 15,000 | $37.32 | $559.7K | 15,000 | |
| KENNEY CHRISTOPHER JOHN 2 fills | Chief Medical Officer | Sell 10b5-1 | 7,068 | $60.25 | $425.8K | 702 −91% of holding | |
| GANNON STEVEN | Director | Sell | 10,000 | $64.06 | $640.6K | 1,870 −84.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.